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Background: It remains unknown as to whether the
antipsychotic dose needed for the acute-phase treat-
ment of schizophrenia is also necessary for relapse
prevention. Aim: To compare the efficacy between stan-
dard dose [(World Health Organization daily defined
dose (DDD)] vs low dose (‡50% to <1 DDD) or very
low dose (<50% DDD) for relapse prevention in schizo-
phrenia. Data source: Double-blind, randomized, con-
trolled trials with a follow-up duration of ‡24 weeks,
including ‡2 dosage groups of the same antipsychotic
drug for relapse prevention in schizophrenia, were
searched using MEDLINE, the Cochrane Central Regis-
ter of Controlled Trials, and EMBASE (last search: Au-
gust 2009). Data extraction: Data on overall treatment
failure, hospitalization, relapse, and dropouts due to
side effects were extracted and combined in a meta-anal-
ysis. Data synthesis: Thirteen studies with 1395 subjects
were included in this meta-analysis. Compared with the
standard-dose treatment, the low-dose therapy did not
show any statistically significant difference in overall
treatment failure or hospitalization, while the standard
dose showed a trend-level (P 5 .05) superiority in risk
of relapse. The very low–dose group was inferior to the
standard-dose group in all efficacy parameters. No sig-
nificant difference was found in the rate of dropouts
due to side effects between either standard dose vs low
dose or very low dose. Conclusions: Although antipsy-
chotic treatment with ‡50% to <1 DDD may be as effec-
tive as standard-dose therapy, there are insufficient
clinical trial data to draw firm conclusions on standard-
vs low-dose maintenance antipsychotic therapy for
schizophrenia.
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Introduction
Antipsychotic drugs have played a central role in the
treatment of schizophrenia for more than 50 years.1 An-
tipsychotic treatment significantly reduces the risk of
relapse; however, this also causes various side effects,
including motor, metabolic, and cardiovascular side
effects,2–5 which contributes to poor adherence and
undesirable outcome.6 Given that the risk for these ad-
verse effects from antipsychotic drugs is often dose-
related,2,4,5 the use of the lowest possible effective
antipsychotic dose for relapse prevention is critically
important to enhance the overall treatment outcome.
While dosing issues of antipsychotic treatment to re-
lieve acute psychotic symptoms of schizophrenia have
been widely investigated,7,8 data are still limited on
the therapeutic dose for relapse prevention. One clini-
cally important question remains unanswered: ‘‘Is the
dose needed for the acute phase also necessary for re-
lapse prevention?’’ In fact, major treatment guidelines
suggest opposite treatment strategies.9–11 For example,
the practice guidelines by the American Psychiatric As-
sociation (APA) recommend the use of the lowest pos-
sible effective dose for the maintenance treatment,9
while the Expert Consensus Guidelines generally advo-
cate the continuous use of antipsychotic dose that was
effective in the acute phase also for relapse preven-
tion.10 To address this gap in knowledge, we conducted
a meta-analysis to compare the efficacy and safety of
standard dose (ie, equal to or more than the defined
daily dose [DDD] by the World Health Organization)
vs low dose (ie, less than the defined dose, but equal
to or greater than half the dose) or very low dose (ie,
less than half the defined dose) for relapse prevention
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in the treatment of schizophrenia or schizoaffective
disorder.
Methods
Study Selection
Double-blind randomized controlled trials (RCTs) in-
cluding at least 2 dosage groups of the same antipsy-
chotic drug for relapse prevention in the maintenance
treatment of schizophrenia or schizoaffective disorder
were identified. MEDLINE (1966–August 2009), the
Cochrane Central Register of Controlled Trials (last
search: August 2009), EMBASE (1980–August 2009),
Current Contents (2001–August 2009), Science Citation
Index Expanded (2005–August 2009), E-Journals
(1832–August 2009), and Science Citation Index Ex-
panded (1900–August 2009) were searched by using
the following search terms: neuroleptic, antipsychotic,
maintenance, relapse, schizophrenia, and schizoaffec-
tive disorder. The reference lists of the relevant study
reports, review articles, and Cochrane reviews were
also examined. No language restriction was applied.
All the titles or abstracts were independently read by
2 of the authors (H.U. and H.T.), and relevant articles
were selected and reviewed. In turn, the reference sec-
tions of articles identified in the search were reviewed
for relevant articles. Pharmaceutical companies that
produced second-generation antipsychotics (SGAs;
Astellas, AstraZeneca, Dainippon-Sumitomo Pharma,
Eli Lilly, Janssen Pharmaceutical, Novartis, Otsuka, and
Pfizer) were asked whether they were aware of further
trials and also invited to provide results of unpublished
trials when available.
Inclusion Criteria
Double-blind RCTs were included if they included
patients with schizophrenia or schizoaffective disorder
(according to the Research Diagnostic Criteria or the
Diagnostic and Statistical Manual of Mental Disorders,
the third edition or later) and had a minimum follow-up
duration of 24 weeks. In addition, to specifically examine
the effect of antipsychotics in relapse prevention, we only
included trials that included patients with stable psycho-
pathology at baseline systematically defined in each indi-
vidual study. We also restricted our analysis to trials that
involved a standard-dose group and at least one of very
low–dose and low-dose groups: (a) standard-dose group,
using a mean dose of 1 DDD unit and less than the up-
per limit of locally approved dose range in the origin of
the trials; (b) very low–dose group, using a mean dose of
<0.5 DDD unit; and (c) low-dose group, using a mean
dose of 0.5 and <1 DDD unit. This unit of measure-
ment used for standardizing antipsychotic doses was
developed by the World Health Organization Collabo-
rating Centre for Drug Statistics Methodology System
of Defined Daily Doses.12 The DDD unit is the assumed
average dose (mg) per day for a drug used for its main
indication in adults (eg, schizophrenia for antipsychotics)
(table 1). In light of the inherent limitations of the DDD
unit system, we also analyzed the data using dosage
ranges recommended by the Schizophrenia Patient Out-
comes Research Team (PORT) Treatment Recommen-
dations (table 1).11 In this second analysis, all
treatment arms in the trials that were identified through
the literature search as described above were sorted to
one of the following dose groups: (a) standard-dose
group, using a mean dose within the PORT-recommen-
ded dose range for the respective medications; (b) very
low–dose group, using a mean dose of less than half
the lower limit of the PORT-recommended dose range;
and (c) low-dose group, using a mean dose of 0.5
and <1 of the lower limit.
In the event of several publications generated by the
same group of investigators that were clearly based on
overlapping samples of subjects, we included data
from the publication with the longest follow-up duration
and/or provided the most detailed information.
Outcome Parameters
The primary outcome of interest was overall treatment
failure, which was defined as the rate of subjects who pre-
maturely discontinued their assigned treatment for any
reason. The secondary outcome parameter was the rate
of subjects who required hospitalization. The rate of sub-
jects who met relapse criteria as defined by the individual
studies was also evaluated. Dropouts due to side effects
were analyzed as a measure of tolerability. Correspond-
ing authors were contacted for missing data. All these
parameters were obtained based on an intention-to-treat
basis. All data were extracted independently by 2 of us
(H.U. and H.T.).
Table 1. DDDs and the PORT-Recommended Dose Ranges of
Included Antipsychotic Drugs for the Maintenance Treatment of
Schizophrenia
Drug Name DDD12
PORT-Recommended
Dose Range11
Quetiapine 400 300–750 mg/d
Ziprasidone 80 120–160 mg/d
Olanzapine 10 10–20 mg/d
Long-acting risperidone 1.8a n.a.
Haloperidol decanoate 3.3b 50–200 mg/4 wks
Fluphenazine decanoate 1c 6.25–25 mg/2 wks
Pimozide 4 n.a.
Propericyazine 50 n.a.
Note: DDD, defined daily dose; PORT: Schizophrenia Patient
Outcomes Research Team; n.a., not available.
aEquivalent to 25.2 mg/2 wks.
bEquivalent to 92.4 mg/4 wks.
cEquivalent to 14 mg/2 wks.
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Statistical Method
The outcome data were combined in a meta-analysis and
were compared between the 3 dose groups as defined
above. The risk difference and its 2-sided 95% confidence
interval (CI) were calculated, with risk difference defined
as (nE = 1, e/ne) – (nE = 1, c/nc) where nE = 1, e is the number
of patients who experienced an event in the experimental
group (ie, low- or very low–dose group), ne is the total
number of patients in the experimental group, nE = 1, c
is the number of patients with the event in the control
group (ie, standard-dose group), and nc is the total num-
ber of patients in the control group. In the case of signif-
icant differences between groups, the number of subjects
needed to treat (NNT) or the number of subjects needed
to harm (NNH) was calculated. NNT or NNH was de-
rived from the risk difference by the formula NNT or
NNH = 1/risk difference, with the 95% CIs of NNT or
NNH being the inverse of the upper and lower limits
of the 95% CI of the risk difference. We also calculated
odds ratios and relative risks. The random-effects model
of DerSimonian and Laird13 was used in all cases because
they take heterogeneity among studies into account.
Study heterogeneity was sought for visual inspection of
the forest plots and by using tau2, chi-square, and the
Higgins I2 tests. Significance levels ofP< .1 were set a pri-
ori to assume the presence of heterogeneity. The overall
test statistic is given by z = risk difference/SE (risk differ-
ence), odds ratio/SE (odds ratio), or relative risk/SE (rel-
ative risk), where SE is a standard error. Funnel plots
were drawn for all outcome parameters to examine pub-
lication bias. Specifically, the effect sizes of the individual
studies were plotted against the standard errors of those
effect sizes.14 These analyses were also performed in a sub-
group of studies that used depot antipsychotics. All the
calculations were performed with Review Manager 5,15
a meta-analytic standard software used by The Cochrane
Collaboration. We usedP values of<.05 and 2-sided 95%
CIs (according to whether the CI included the null value)
to assess significance.
Results
Included Studies
A total of 13 studies, involving 1395 subjects (739 in stan-
dard-dose groups, 457 in low-dose groups, and 199 in
very low–dose groups), were included in this meta-
analysis (tables 2 and 3).16–28 The reasons for excluding
the remaining studies are detailed in figure 1. No addi-
tional data were provided by any of the pharmaceutical
companies approached by the investigators. We could
not locate any relevant unpublished study with another
search in the ClinicalTrials.gov or the Food and Drug
Administration Web site. Eight and seven studies in-
cluded low- and very low–dose groups, respectively.
Long-acting injectable antipsychotic drugs were included
in 1 out of the 4 studies using SGAs, and 7 out of the 9
studies using first-generation antipsychotics (FGAs). The
study duration of included studies ranged between 24 and
104 weeks, and a follow-up at 1 year or beyond was per-
formed in all but 2 studies. The mean age of the subjects
ranged from 28.3 to 50.1 years. Twelve studies included
clinically stable ambulatory patients, and one study in-
cluded hospitalized patients who presented with stable
psychopathology. Funnel plots did not suggest any obvi-
ous publication bias for efficacy outcome parameters,
whereas the plots on dropouts due to side effects in com-
parisons between low dose vs standard dose and between
very low dose vs standard dose were asymmetrical.
Overall Treatment Failure
Low-dose group did not show any statistically significant
difference in comparison with standard-dose group in
terms of the rate of subjects who discontinued their
assigned treatment for any reason (figure 2). The upper
limit of the 95% CI of risk difference was as low as 0.10.
On the other hand, the very low–dose treatment was
found to be inferior to the standard-dose therapy in over-
all treatment failure (NNH = 8, 95% CI = 4–50; figure 2).
Hospitalization
The rate of subjects who needed hospitalization was
reported in a total of 9 studies (5 studies each comparing
low vs standard doses and very low vs standard doses).
While no significant difference was found in subsequent
admission to hospital between low-dose and standard-
dose therapies, the very low–dose treatment was inferior
to the standard-dose therapy (NNH = 9, 95% CI = 6–25;
figure 3).
Relapse
Definitions of relapse differed widely among studies, and
3 studies did not report any data on relapse. Since the rate
of subjects who needed hospitalization was available in 2
of those 3 studies, the need for hospitalization was taken
as a proxy for relapse in our analysis for these 2 studies.
Hence, the rate of subjects who relapsed was available in
a total of 12 studies. Similar to the findings in the hospi-
talization rate, the very low–dose treatment was inferior
to the standard-dose therapy (NNH = 4, 95% CI = 3–8).
No statistically significant difference was found in risk of
relapse between low-dose and standard-dose therapies;
however, it should be noted that the P value barely
exceeded .05 (figure 4). The results were heterogeneous
in the analysis comparing between very low dose
vs standard dose (tau2 = 0.02; chi square = 12.1, degrees
of freedom [df] = 5, P = .03; I2 = 59%).
Side Effects
No significant difference was found in the rate of subjects
who withdrew from their assigned medication due to side
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Table 2. Characteristics of the 13 Included Studies
Study Antipsychotic
Standard-Dose
Group: Dose (N)
Low-Dose
Group: Dose (N)
Very Low–Dose
Group: Dose (N)
Study
Duration
(wks)
Mean
Age of
Subjects (y)
Second generation antipsychotics
Dellva et al16 Olanzapine (oral) 5–15 (mean, 11.5) mg/
d (N = 48)
— 1 mg/d (N = 14) 46 37.0
Velligan et al17 Quetiapine 600 mg/d (N = 52) 300 mg/d (N = 41) — 24 40.7a
Arato et al18 Ziprasidone (oral) 80 or 160 mg/d (N = 135) 40 mg/d (N = 72) — 52 50.1
Simpson et al19 Risperidone (long-
acting)
50 mg/2 wks (N = 161) 25 mg/2 wks (N = 162) — 52 40.9
First generation antipsychotics
Kane et al20 Fluphenazine decanoate 12.5–50 mg/2 wks
(N = 64)
— 1.25–5 mg/2 wks
(N = 62)
52 28.9
Nishikawa et al21 Propericyazine 60 mg/d (N = 12) 30 mg/d (N = 12) 10 mg/d (N = 13) 52 39.3
Nishikawa et al22 Pimozide 6 mg/d (N = 11) 2 mg/d (N = 13) — 52 38.6
Marder et al23 Fluphenazine decanoate 25 mg/2 wks (N = 31) — 5 mg/2 wks (N = 35) 104 36.5
Hogarty et al24 Fluphenazine decanoate Mean, 25 mg/2 wks
(N = 33)
— Mean 3.8 mg/2 wks
(N = 37)
104 28.3
Inderbitzin et al25 Fluphenazine decanoate Mean, 47.2 mg/4 wks
(N = 20)b
Mean, 22.7 mg/4 wks
(N = 23)b
— 52 40.9b
Huttunen et al26 Haloperidol decanoate 150 mg/4 wks (N = 13) — 25 mg/4 wks (N = 13) 104 <45
Schooler et al27 Fluphenazine decanoate 12.5–50 mg/2 wkse
(N = 107)c
2.5–10 mg/2 wksd (N =
106)
— 104 29.6e
Kane et al28 Haloperidol decanoate 100 or 200 mg/4 wks
(N = 52)
50 mg/4 wks (N = 28) 25 mg/4 wks (N = 25) 52 38.5
Note: BPRS, Brief Psychiatric Rating Scale.
aThe mean age in 43 completers.
bData from participants who completed all study procedures.
cWhen participants showed prodromal sign of relapse, rescue medication (either oral fluphenazine or fluphenazine decanoate) was added until patients were restabilized. The
mean value (ie, the dosage for the first 6-mo period, including rescue medication) was 30.9 mg/2 wks.
dWhen participants showed prodromal sign of relapse, rescue medication (either oral fluphenazine or fluphenazine decanoate) was added until patients were restabilized. The
mean value (ie, the dosage for the first 6-mo period, including rescue medication) was 13.3 mg/2 wks.
eData from the entire sample, including targeted dose group.
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effects between either low dose vs standard dose or very
low dose vs standard dose (figure 5). This finding was rep-
licated also when SGAs and FGAs were separately ana-
lyzed. The results were heterogeneous in the analyses
comparing both between very low dose vs standard
dose (tau2 = 0.00; chi square = 10.1, df = 4, P = .04;
Table 3. Summary of Definitions of Remission and Relapse in the 13 Included Studies
Study
Main Definition of Remission or Partial
Remission at Baseline Definition of Relapse
Second generation antipsychotics
Dellva et al16 Outpatients who had responded to acute
therapy, using the same dose (ie, >40%
reduction in the BPRS total score)
Hospitalization for psychopathology
Velligan et al17 Outpatients; BPRS: 3 on conceptual
disorganization unusual thought content,
hallucinatory behavior, and suspiciousness
Not indicated
Arato et al18 Inpatients; CGI-S: 5; PANSS: 4 on
hostility and uncooperativeness
6 on CGI-I or 6 on PANSS hostility
and/or uncooperativeness
Simpson et al19 Outpatients; no hospitalization for
psychopathology within the past 4 mo
Hospitalization for psychopathology, 6
on CGI-I, or 25% increase in total PANSS
score
First generation antipsychotics
Kane et al20 Outpatients; GAS: 35; BPRS: 4 on
conceptual disorganization and
hallucinatory behavior, 5 on
suspiciousness, and 3 on unusual thought
content
For patients entering with scores 2 below
the maximum allowable, an increase in any
of the 4 BPRS items in the inclusion criteria
to the maximum allowable. For patients
entering with scores <2 below the maximum
allowable, a 2 increase in any of the 4
BPRS items
Nishikawa et al21 Outpatients; ‘‘the recovery stage of
remission or residual phase’’
Clinical worsening on physicians’ judgment
Marder et al23 Outpatients; being stabilized with 25 mg
of fluphenazine decanoate/2 wks for 2 mo
Continuation of a 3 increase on either the
thought disturbance cluster (conceptual
disorganization, hallucination, and unusual
thought content) or paranoid cluster
(hostility, uncooperativeness, and
suspiciousness) in the BPRS, following the
dose incrementa,b
Hogarty et al24 Outpatients; the lack of marked influence of
hallucinations or delusions on behavior; no
evidence of moderate or severe deterioration
Changes from 1 or 2 to 4 or 5 on conceptual
disorganization and/or unusual thought
content, hallucinations, and delusions in the
BPRS
Inderbitzin et al25 Outpatients; receiving 20 mg of
fluphenazine decanoate/4 wks for 2 mo
Any exacerbation requiring hospitalization
and/or addition of neuroleptic or anxiolytic
Huttunen et al26 Outpatients or inpatients who were just
about to be discharged
Not indicated (the number of patients
requiring hospitalization was available)
Schooler et al27 Outpatients; BPRS: 4 on conceptual
disorganization, grandiosity, hallucinatory
behavior, and unusual thought content
4 on conceptual disorganization,
grandiosity, hallucinatory behavior, or
unusual thought subscale in the BPRS
exceeded (the number of relapsed patients
was not available)
Kane et al28 Outpatients; BPRS: 3 on conceptual
disorganization unusual thought content
and 4 on hallucinatory behavior and
suspiciousness
A 3-point increase on any of the 4 BPRS
items listed in the inclusion criteria
Note: BPRS, Brief Psychiatric Rating Scale; CGI-S, Clinical Global Impression, severity of illness; CGI-I, Clinical Global Impression,
global improvement; PANSS, Positive and Negative Syndrome Scale; GAS, Global Assessment Scale.
aWhen a 3 increase on either the thought disturbance cluster (conceptual disorganization, hallucination, and unusual thought
content) or paranoid cluster (hostility, uncooperativeness, and suspiciousness) in the BPRS occurred, the dose was increased to 50 mg/
2 wks.
bWhen a 3 increase on either the thought disturbance cluster (conceptual disorganization, hallucination, and unusual thought content)
or paranoid cluster (hostility, uncooperativeness, and suspiciousness) in the BPRS occurred, the dose was increased to 10 mg/2 wks.
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I2 = 60%) and between low dose vs standard dose
(tau2 = 0.08; chi square = 20.3, df = 2,P< .0001; I2 = 90%).
Relative Risks and Odds Ratios
The presence and lack of statistically significant differen-
ces when risk differences were calculated were also ob-
served when relative risks or odds ratios were
obtained, respectively, other than the relative risk for
dropouts due to side effects between very low–dose
and standard-dose therapies (table 4).
Low Dose vs Very Low Dose
A total of 2 studies, involving 78 subjects (40 in low-dose
groups and 38 in very low–dose groups), included low-
dose and very low–dose treatment arms (tables 1 and
2).21,28 Despite a small number of included studies, we
found that the very low–dose treatment was inferior to
the low-dose therapy in overall treatment failure and
relapse (NNH = 5, 95% CI = 3–33; NNH = 5, 95%
CI = 3–50, respectively; figure 6).
Depot Antipsychotics
A total of 8 studies, involving 1395 subjects (481 in stan-
dard-dose groups, 319 in low-dose groups, and 172 in
very low–dose groups), used depot antipsychotics (tables
2 and 3).19,20,23–28 Results of this subgroup analysis were
similar to those that were demonstrated in the whole data
set. Low-dose group did not show any statistically signif-
icant difference in comparison with standard-dose group
in terms of any of the outcome measures, including the
rate of subjects who discontinued their assigned treat-
ment for any reason (Supplementary Figures 1–4). On
the other hand, the very low–dose treatment was found
to be inferior to the standard-dose therapy in overall
treatment failure, hospitalization, and relapse (NNH =
6, 95% CI = 4–20; NNH = 10, 95% CI = 6–25; NNH =
5, 95% CI = 3–25, respectively; Supplementary Figures
1–4).
Dose Group Classification According to the PORT
Treatment Recommendations
Out of the 13 studies identified through the literature
search, 7 studies were excluded for the following reasons:
(1) recommended dose range was not available for stud-
ied antipsychotics—3 studies: Simpson et al,19 Nishikawa
et al,21 and Nishikawa22; (2) all tested doses were within
the PORT-recommended dose range—3 studies: Velligan
et al,17 Inderbitzin et al,25 and Schooler et al27; and (3) since
a mean dose was not specified, it was not possible to group
the treatment arm (eg, fluphenazine decanoate 1.25–5 mg/
2 wks) to either low- or very low–dose group—1 study:
Kane et al.20 Thus, the remaining 6 studies16,18,23,24,26,28
were included (Supplementary Table 1). Low-dose group
did not show any statistically significant difference in com-
parison with standard-dose group in any of the outcome
measures, including the rate of subjects who discontinued
their assigned treatment for any reason (Supplementary
Figures 5–8). Similarly, no significant difference was found
between very low– or low- and standard-dose treatments
(Supplementary Figure 9).
Discussion
To our knowledge, this is the first meta-analysis of the
long-term efficacy of very low, low, and standard anti-
psychotic dose therapies for schizophrenia. The system-
atic review revealed a lack of sufficient clinical trial data
Fig. 1. Flowchart of Literature Search.
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to draw firm conclusions on the maintenance of antipsy-
chotic dose in schizophrenia and schizoaffective disorder.
This notwithstanding, the analyses yield 2 important
findings: (a) low-dose therapy may be as effective as stan-
dard-dose therapy in terms of efficacy, and (b) less than
half the standard dose is likely to be associated with the
increased risk of treatment failure. This is in contrast to
the contention that the dose needed for relapse preven-
tion should be the same as that for the acute-phase treat-
ment.10 The study has several limitations, which we
discuss below, but, notwithstanding these limitations,
our findings provide an opportunity to reconsider an ef-
fective psychopharmacological treatment strategy for re-
lapse prevention in clinically stable patients with
schizophrenia or schizoaffective disorder.
Overall treatment failure due to any reason has recently
been suggested to be a clinically pragmatic treatment out-
come.29 A decision to continue or stop medication
reflects the combined evaluation of the efficacy and safety
of the treatment by the patient and clinician.29 For this
reason, this outcome measure has extensively been used
in many pivotal clinical trials, including Clinical
Antipsychotic Trials of Intervention Effectiveness.30 An-
other relevant and explicit index may be hospitalization
that patients needed. Although demonstrating a noninfer-
iority of the treatment of interest to a standard treatment
is often associated with difficulties,31 the finding that the
upper limit of 95% CI of risk difference for overall treat-
ment failure and hospitalization were as low as 0.10 and
0.07, respectively, may be suggestive of a comparable ef-
ficacy between low- and standard-dose treatments. On
the other hand, our analysis showed that very low
dose was associated with worse outcomes in terms of
those 2 outcome measures as compared with standard
dose and clearly do not support the use of less than
half the standard dose for relapse prevention. However,
clinical conditions that result in treatment failure or re-
quire hospitalization are likely to widely differ among
treatment or research settings. It would have been ideal
to compare changes in psychopathology assessed with
Fig. 2. Risk of Overall Treatment Failure. SGA: second-generation antipsychotic; FGA: first-generation antipsychotic; CI: confidence
interval.
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a rating scale; however, the detailed data were not avail-
able in a majority of studies that were included in this
meta-analysis. These facts highlight an urgent need of
well-designed prospective studies in schizophrenia to fur-
ther address the need to balance drug exposure and re-
lapse prevention.
The treatment strategy for the maintenance phase of
schizophrenia is still under debate; indeed, polar recom-
mendations are issued by some currently published treat-
ment guidelines. While the practice guidelines by the
APA9 and the Schizophrenia PORT Treatment Recom-
mendations11 support the low-dose treatment to mini-
mize antipsychotic side effects, the Expert Consensus
Guidelines generally recommend the use of the antipsy-
chotic dose that was needed for acute-phase treatment to
lower the risk of relapse.10 These inconsistent recommen-
dations may be in part due to a difference in timing of
publications; however, interestingly, even in the Expert
Consensus Guidelines, the recommendations by experts
were split, indicating an absence of consensus on this is-
sue in the field. Although both treatment strategies seem
to have rationales, maintaining acute doses is a strategy
that seems to be heavily based on the results of previous
trials that compared very low dose with standard
dose.28,32 In fact, the trials conducted in the 1980s, includ-
ing a very low dose (eg, fluphenazine decanoate 5 mg/
2 wks),20,23,24 have been often cited to support this
contention. The only and first meta-analysis on the
maintenance dose of antipsychotics32 before the present
article was also substantially influenced by those trials,
which in turn led to a conclusion that standard-dose
treatment was more efficacious than ‘‘low’’-dose therapy.
Thus, it is this lack of distinction between low and very
low doses in the earlier studies that led to the discrepant
conclusions.
In the present study, we did not find any statistically
significant difference in the rate of subjects who discon-
tinued their assigned treatment due to side effects
among dosage groups. However, a variety of side
effects, including motor and cardiac side effects, have
been reported to occur in a dose-dependent fashion.2,4,5
An association between a greater degree of exposure to
antipsychotic drugs and a higher risk for sudden cardiac
death has also been confirmed for both typical and atyp-
ical antipsychotic drugs.4 Furthermore, a higher dose
of several antipsychotics results in a greater prolactin
level elevation,33 which is suggested to be associated
with problematic adverse effects, including menstrual
Fig. 3. Risk of Hospitalization. SGA: second-generation antipsychotic; FGA: first-generation antipsychotic; CI: confidence interval.
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disturbances. In addition, somnolence has been
reported to occur more frequently with standard-dose
therapy (20 and 24 mg/d of sertindole; 8 and 16 mg/d of ha-
loperidol) than low-dose treatment (12 mg/d of sertindole;
4 mg/d of haloperidol), respectively.34 Given these dose-
dependent side effects of antipsychotics, a moderately
low dose may be the optimal target in clinical practice
in order to balance the desired maintenance of therapeutic
benefits and the dose-dependent adverse effects. All the
studies included in this meta-analysis were not specifically
designed to evaluate dose effects of antipsychotic drugs on
side effects, and the lack of detailed information on side
effects in those trials limits the interpretation of our results.
Given the lack of significant finding in this meta-analysis,
this potential dose effect on side effects that has been
reported in the literature has to be confirmed in future
investigations.
Several limitations qualify our conclusions. First, the
number of studies included in the present meta-analysis
was relatively small, especially for SGAs. Although a sub-
group of 4 trials, using SGAs, demonstrated similar
results to those that were found in FGA studies, a relative
underestimation of studies on SGAs should be acknowl-
edged and warrants further investigations. Second, study
designs, including selection criteria, definition of stable
psychopathology at baseline, outcome measures, and
studied antipsychotic drugs, differ among individual
trials, although this is not a unique limitation to our
meta-analysis. However, the use of DDD and common
outcome measures, such as overall treatment failure
and hospitalization instead of ‘‘relapse,’’ are expected
to counteract this limitation to some extent. In fact,
the DDD system has been developed as an international
standard for drug utilization studies, and 1 DDD of each
drug has a robust rationale. The fact that we found sim-
ilar findings when using PORT-recommended dosage
ranges support our findings with DDD. However, given
a very small number of included studies, the lack of sta-
tistically significant difference in efficacy between dose
groups may be due to a type-II error, which warrants fur-
ther well-designed prospective clinical trials on the main-
tenance antipsychotic treatment for schizophrenia.
Third, the low dose and very low dose were conveniently
defined, using a cut-off point of 0.5 DDD. However, this
categorical distinction between ‘‘very low’’ and ‘‘low’’
suggests a discrete dose threshold that divides them, while
Fig. 4. Risk of Relapse. SGA: second-generation antipsychotic; FGA: first-generation antipsychotic; CI: confidence interval.
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it is more likely that the continuous nature of dose-re-
sponse may necessitate a more gradual dose adjustment.
For example, 0.5 DDD may not be the same as 0.9 DDD
in terms of therapeutic or side effects, although they
would be sorted into the same low-dose group. In fact,
a treatment arm with 25 mg/2 wks of long-acting risper-
idone was included in the low-dose group though its
DDD was very close to 1.0. This fact has to be acknowl-
edged, especially when applying the findings of this study
to daily clinical practice.
In conclusion, we report on the systematic review and
meta-analysis of dose effects of antipsychotics for re-
lapse prevention in schizophrenia. The currently avail-
able evidence suggests that the efficacy of low- and
Fig. 5. Risk of Dropout due to Side Effects. SGA: second-generation antipsychotic; FGA: first-generation antipsychotic; CI: confidence
interval.
Table 4. Relative Risks and Odds Ratios
Outcome Parameters
Relative Risk Odds Ratio
Ratio 95% CI z P Ratio 95% CI z P
Low dose vs standard dose
Overall treatment failure 1.05 0.93–1.17 0.78 .43 1.09 0.84–1.40 0.62 .53
Hospitalization 1.12 0.77–1.62 0.58 .56 1.16 0.73–1.85 0.65 .52
Relapse 1.25 1.00–1.55 1.98 .05 1.35 0.99–1.84 1.91 .06
Dropouts due to side effects 0.70 0.41–1.19 1.32 .19 0.60 0.26–1.39 1.20 .23
Very low dose vs standard dose
Overall treatment failure 1.24 1.02–1.52 2.12 .03 2.07 1.24–3.45 2.77 .006
Hospitalization 2.21 1.16–4.23 2.40 .02 2.70 1.21–6.02 2.42 .02
Relapse 2.75 1.56–4.84 3.50 .0005 4.16 1.85–9.38 3.44 .0006
Dropouts due to side effects 0.38 0.15–0.95 2.06 .004 0.27 0.05–1.42 1.54 .12
CI: confidence interval.
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standard-dose antipsychotic medication may be compa-
rable in preventing relapse in schizophrenia and schiz-
oaffective disorders, and that less than half the
standard dose may increase the risk of treatment failure.
However, these results have to be interpreted in light of
a small number of relevant studies in the literature. We
acknowledge individual differences in patient’s response
to antipsychotics on various pharmacokinetic and phar-
macodynamic levels,35–37 precluding our ability to pro-
pose a uniformed treatment approach for relapse
prevention.38 Still, the intriguing observations from
this meta-analysis have important implications for the
dosing of antipsychotics in patients with schizophrenia
and urge the field to perform further well-designed
prospective clinical trials to address this controversial
dosing issue.
Supplementary Material
Supplementary Figures 1–9 and Table 1 are available at
http://schizophreniabulletin.oxfordjournals.org.
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